Spinnaker ETF Series - North Shore Equity Rotation ETF
US ˙ ARCA ˙ US1571313014

Introduction

This page provides a comprehensive analysis of the known insider trading history of Matthew T Plavan. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Matthew T Plavan has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ORGN / Origin Materials, Inc. CFO and COO 1,510,231
US:RKDA / Arcadia Biosciences, Inc. Chief Executive Officer 435,450
US:KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF Former CEO 245,066
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Matthew T Plavan. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF Insider Trades
Insider Sales KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2015-09-02 KOOL Plavan Matthew T 11,400 0.6800 11,400 0.6800 7,752 731
2015-09-02 KOOL Plavan Matthew T 5,871 0.6875 5,871 0.6875 4,036

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF Insider Trades
Insider Purchases ORGNW / Origin Materials, Inc. - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ORGNW / Origin Materials, Inc. - Equity Warrant Insider Trades
Insider Sales ORGNW / Origin Materials, Inc. - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-05 ORGN Plavan Matthew T 9,725 0.8579 9,725 0.8579 8,343 100 0.4213 -4,246 -50.89
2024-11-04 ORGN Plavan Matthew T 120,000 1.3155 120,000 1.3155 157,860

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ORGNW / Origin Materials, Inc. - Equity Warrant Insider Trades
Insider Purchases RKDA / Arcadia Biosciences, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2020-08-03 RKDA Plavan Matthew T 585 3.1600 15 126.4000 1,849 191 227.6 1,338 72.42
2020-02-03 RKDA Plavan Matthew T 700 1.7200 18 68.8000 1,204
2019-11-14 RKDA Plavan Matthew T 1,000 4.0795 25 163.1800 4,080
2019-09-23 RKDA Plavan Matthew T 2,000 5.2500 50 210.0000 10,500
2019-09-10 RKDA Plavan Matthew T 1,000 6.4930 25 259.7200 6,493
2019-09-10 RKDA Plavan Matthew T 1,000 6.5205 25 260.8200 6,520
2019-08-28 RKDA Plavan Matthew T 1,000 6.8800 25 275.2000 6,880
2019-08-27 RKDA Plavan Matthew T 1,000 9.3200 25 372.8000 9,320
2019-08-27 RKDA Plavan Matthew T 1,000 9.3000 25 372.0000 9,300
2019-08-27 RKDA Plavan Matthew T 1,000 8.9500 25 358.0000 8,950
2019-08-27 RKDA Plavan Matthew T 2,000 8.9300 50 357.2000 17,860
2019-08-26 RKDA Plavan Matthew T 1,000 8.3300 25 333.2000 8,330
2019-08-26 RKDA Plavan Matthew T 1,000 9.2200 25 368.8000 9,220

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RKDA / Arcadia Biosciences, Inc. Insider Trades
Insider Sales RKDA / Arcadia Biosciences, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in KOOL / Spinnaker ETF Series - North Shore Equity Rotation ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RKDA / Arcadia Biosciences, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Matthew T Plavan as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-07 2025-03-05 4 ORGN Origin Materials, Inc.
Common Stock
S - Sale -9,725 1,510,231 -0.64 0.86 -8,343 1,295,627
2025-02-28 2025-02-26 4 ORGN Origin Materials, Inc.
Common Stock
A - Award 80,368 1,519,956 5.58
2024-12-31 2024-12-27 4 ORGN Origin Materials, Inc.
Common Stock
S - Sale X -24,500 1,439,588 -1.67 1.02 -25,110 1,475,434
2024-12-31 2024-12-23 4 ORGN Origin Materials, Inc.
Common Stock
A - Award 241,000 1,464,088 19.70
2024-11-06 2024-11-04 4 ORGN Origin Materials, Inc.
Common Stock
S - Sale -120,000 1,223,088 -8.93 1.32 -157,860 1,608,972
2023-12-28 2023-12-26 4 ORGN Origin Materials, Inc.
Common Stock
A - Award 241,105 1,343,088 21.88
2023-11-01 3 ORGN Origin Materials, Inc.
No securities owned.
0
2023-11-01 2023-10-30 4 ORGN Origin Materials, Inc.
Common Stock
A - Award 1,101,983 1,101,983
2021-01-25 2021-01-21 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 250,000 435,450 134.81
2021-01-25 2020-08-03 4 RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 585 14,285 4.27 3.16 1,849 45,141
2020-02-04 2020-02-03 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 76,000 185,450 69.44
2020-02-04 2020-02-03 4 RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 700 13,700 5.38 1.72 1,204 23,564
2019-11-18 2019-11-14 4 RKDA Arcadia Biosciences, Inc.
Common stock
P - Purchase 1,000 13,000 8.33 4.08 4,080 53,034
2019-09-23 2019-09-23 4 RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 2,000 12,000 20.00 5.25 10,500 63,000
2019-09-10 2019-09-10 4 RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 1,000 10,000 11.11 6.52 6,520 65,205
2019-09-10 2019-09-10 4 RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 1,000 9,000 12.50 6.49 6,493 58,437
2019-08-28 2019-08-28 4 RKDA Arcadia Biosciences, Inc.
Common Stock
A - Award 1,000 8,000 14.29 6.88 6,880 55,040
2019-08-28 2019-08-27 4 RKDA Arcadia Biosciences, Inc.
Common Stock
A - Award 2,000 7,000 40.00 8.93 17,860 62,510
2019-08-28 2019-08-27 4 RKDA Arcadia Biosciences, Inc.
Common Stock
A - Award 1,000 5,000 25.00 8.95 8,950 44,750
2019-08-28 2019-08-27 4 RKDA Arcadia Biosciences, Inc.
Common Stock
A - Award 1,000 4,000 33.33 9.30 9,300 37,200
2019-08-28 2019-08-27 4 RKDA Arcadia Biosciences, Inc.
Common Stock
A - Award 1,000 3,000 50.00 9.32 9,320 27,960
2019-08-28 2019-08-26 4 RKDA Arcadia Biosciences, Inc.
Common Stock
A - Award 1,000 2,000 100.00 9.22 9,220 18,440
2019-08-28 2019-08-26 4 RKDA Arcadia Biosciences, Inc.
Common Stock
A - Award 1,000 1,000 8.33 8,330 8,330
2019-08-28 2019-08-28 4/A RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 1,000 8,000 14.29 6.88 6,880 55,040
2019-08-28 2019-08-27 4/A RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 2,000 7,000 40.00 8.93 17,860 62,510
2019-08-28 2019-08-27 4/A RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 1,000 5,000 25.00 8.95 8,950 44,750
2019-08-28 2019-08-27 4/A RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 1,000 4,000 33.33 9.30 9,300 37,200
2019-08-28 2019-08-27 4/A RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 1,000 3,000 50.00 9.32 9,320 27,960
2019-08-28 2019-08-26 4/A RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 1,000 2,000 100.00 9.22 9,220 18,440
2019-08-28 2019-08-26 4/A RKDA Arcadia Biosciences, Inc.
Common Stock
P - Purchase 1,000 1,000 8.33 8,330 8,330
2019-06-07 2019-06-03 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 26,000 109,450 31.16
2018-09-20 2018-09-18 4 RKDA Arcadia Biosciences, Inc.
Stock Option (Right to Buy)
A - Award 47,200 83,450 130.21
2017-06-09 2017-06-08 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 225,000 225,000
2016-09-12 2016-09-12 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 37,500 37,500
2016-09-12 2016-09-12 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 37,500 37,500
2016-09-12 2016-09-12 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 150,000 150,000
2016-09-12 2016-09-12 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 150,000 150,000
2016-09-12 2016-09-12 4 RKDA Arcadia Biosciences, Inc.
Stock Option (right to buy)
A - Award 125,000 125,000
2015-09-04 2015-09-02 4 KOOL CESCA THERAPEUTICS INC.
Common Stock
S - Sale -5,871 245,066 -2.34 0.69 -4,036 168,483
2015-09-04 2015-09-02 4 KOOL CESCA THERAPEUTICS INC.
Common Stock
S - Sale -11,400 250,937 -4.35 0.68 -7,752 170,637
2015-04-17 2014-06-01 4/A KOOL CESCA THERAPEUTICS INC.
Common Stock
F - Taxes -3,395 302,090 -1.11 1.71 -5,805 516,574
2015-04-17 2013-07-29 4/A KOOL CESCA THERAPEUTICS INC.
Common Stock
F - Taxes -8,402 95,485 -8.09 1.16 -9,746 110,763
2015-04-17 2013-06-01 4/A KOOL CESCA THERAPEUTICS INC.
Common Stock
F - Taxes -3,300 103,887 -3.08 1.17 -3,861 121,548
2015-04-17 2012-07-29 4/A KOOL CESCA THERAPEUTICS INC.
Common Stock
F - Taxes -8,263 107,187 -7.16 0.88 -7,271 94,325
2015-04-17 2012-06-01 4/A KOOL CESCA THERAPEUTICS INC.
Common Stock
F - Taxes -3,300 115,450 -2.78 0.87 -2,871 100,442
2014-12-09 2014-12-05 4 KOOL CESCA THERAPEUTICS INC.
Common Stock
F - Taxes -23,765 262,337 -8.31 1.05 -24,953 275,454
2014-08-21 2014-08-19 4 KOOL CESCA THERAPEUTICS INC.
Option
A - Award 400,000 762,500 110.34
2014-07-31 2014-07-29 4 KOOL CESCA THERAPEUTICS INC.
Common Stock
F - Taxes -8,488 293,602 -2.81 1.39 -11,798 408,107
2014-03-05 2014-03-03 4 KOOL CESCA THERAPEUTICS INC.
Option
A - Award 100,000 362,500 38.10
2014-03-05 2014-03-03 4 KOOL CESCA THERAPEUTICS INC.
Common Stock
A - Award 210,000 305,485 219.93
2012-08-01 2012-07-30 4 KOOL THERMOGENESIS CORP
Option
A - Award 162,500 325,000 100.00
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)